Novartis psoriasis drug superior to Enbrel in study

ZURICH (Reuters) - Novartis psoriasis drug secukinumab was superior to Amgen's Enbrel in a late-stage study, the Swiss company said on Monday, putting it in line to become the first of a clutch of new treatments to gain market approval.

Source: Reuters: Health - July 10, 2013 Category: Consumer Health News Tags: healthNews Source Type: news